Feed aggregator

CN NS: Making Their Voices Heard

MAP - Hemp - Tue, 08/29/2017 - 07:00
The Journal-Pioneer, 29 Aug 2017 - Supporters of marijuana advocate protest outside Amherst courthouse Support for a Cumberland County man charged with marijuana and firearm offences showed up early Monday for his first court appearance since being arrested almost a week ago.

CN NS: Making Their Voices Heard

MAP - Cannabis - Tue, 08/29/2017 - 07:00
The Journal-Pioneer, 29 Aug 2017 - Supporters of marijuana advocate protest outside Amherst courthouse Support for a Cumberland County man charged with marijuana and firearm offences showed up early Monday for his first court appearance since being arrested almost a week ago.

CN MB: Town Hall To Bring Clarity On Legal Pot

MAP - Cannabis - Tue, 08/29/2017 - 07:00
Metro, 29 Aug 2017 - A town hall in St. James Tuesday night will try to clear the air for any Winnipeggers with questions about cannabis legalization in advance of a legislation review this fall. Hosted by Charleswood-St. James-Assiniboia-Headingley MP Doug Eyolfson, the event will feature an in-depth review of Bill C-45-which would amend the Controlled Drugs and Substances Act, Criminal Code and other acts-expert testimony from witnesses at the federal health committee.

CN QU: Legal Pot, But At What Price?

MAP - Cannabis - Tue, 08/29/2017 - 07:00
The Record, 29 Aug 2017 - Provinces agree marijuana cost, quality and access must be competitive with black market: Blair MONTREAL - There is an overwhelming national consensus that legal marijuana must be priced, taxed and made available competitively with the black market, the man tasked with leading the drug's legalization in Canada said Monday.

CN NS: Tasty Budds Dispensaries Reopen

MAP - Cannabis - Tue, 08/29/2017 - 07:00
Metro, 29 Aug 2017 - 'Alleged illegal activity' only at one location All five Tasty Budds medical marijuana dispensaries in Nova Scotia have reopened following raids last week, and allegations of illegal activity that the chain's owner says were confined to just one location.

FDA Grants Breakthrough Therapy Designation to MDMA (Ecstasy) for PTSD

The Joint Blog - Mon, 08/28/2017 - 22:06
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA (the main compound found in ecstasy) for the treatment of posttraumatic stress disorder (PTSD).

The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of posttraumatic stress disorder (PTSD). MAPS and the FDA have also reached agreement under the Special Protocol Assessment Process (SPA) for the design of two upcoming Phase 3 trials (MAPP1 and MAPP2) of MDMA-assisted psychotherapy for patients with severe PTSD.

MDMA-assisted psychotherapy is a novel treatment package that combines psychotherapeutic techniques with three administrations of MDMA as a pharmacological adjunct.

By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD.

The first Phase 3 trial (MAPP1), “A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder,” will begin enrolling subjects in Spring 2018, after the completion of an open-label lead-in training study at Phase 3 sites starting this fall.

“Reaching agreement with FDA on the design of our Phase 3 program and having the ability to work closely with the agency has been a major priority for our team,” said Amy Emerson, Executive Director of the MAPS Public Benefit Corporation (MPBC). “Our Phase 2 data was extremely promising with a large effect size, and we are ready to move forward quickly. With breakthrough designation, we can now move even more efficiently through the development process in collaboration with the FDA to complete Phase 3.”

“For the first time ever, psychedelic-assisted psychotherapy will be evaluated in Phase 3 trials for possible prescription use, with MDMA-assisted psychotherapy for PTSD leading the way,” said Rick Doblin, Founder and Executive Director of MAPS. “Now that we have agreement with FDA, we are ready to start negotiations with the European Medicines Agency.”

The Phase 3 trials will assess the efficacy and safety of MDMA-assisted psychotherapy in 200-300 participants with PTSD, aged 18 and older, at sites in the U.S., Canada, and Israel. Participants will be randomized to receive three day-long sessions of either MDMA or placebo in conjunction with psychotherapy over a 12-week treatment period, along with 12 associated 90-minute non-drug preparatory and integration sessions. The primary endpoint will be the Clinician Administered PTSD Scale (CAPS-5), as assessed by a blinded pool of independent raters.

In MAPS’ completed Phase 2 trials with 107 participants, 61% no longer qualified for PTSD after three sessions of MDMA-assisted psychotherapy two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. All Phase 2 participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.

MDMA transiently increases heart rate, blood pressure, and body temperature in a dose-dependent manner that is generally not problematic for physically healthy individuals. Serious Adverse Events involving administration of MDMA in MAPS studies have been uncommon and non-life threatening. Phase 2 trial results are currently being prepared for publication.

About Breakthrough Therapies

The FDA grants Breakthrough Therapy Designation to treatments that (1) are intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition; and (2) preliminary clinical evidence indicates may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Since 2012, the FDA has implemented this program to expedite the development and review of any treatment designated as a breakthrough therapy. For more information, see the FDA’s Fact Sheet.

About Special Protocol Assessments

The Special Protocol Assessment (SPA) process is an agreement resulting from official evaluation and written guidance from FDA on the protocol design, clinical endpoints, planned conduct, and statistical analyses for the Phase 3 trial to ensure they are acceptable to support regulatory approval. Final marketing approval depends on the efficacy results, adverse event profile, and an evaluation of the ratio of risks and treatment benefits demonstrated in the Phase 3 clinical program. The SPA agreement may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. For more information, see the FDA’s Guidance for Industry.

About MDMA-Assisted Psychotherapy

MDMA-assisted psychotherapy is a novel treatment package that combines psychotherapy with the administration of MDMA (approved generic name: midomafetamine) to achieve significant and lasting reductions in PTSD symptoms. MDMA is administered in three single-dose psychotherapy sessions administered in a clinic setting spaced three to five weeks apart, along with preparatory and integration sessions. Phase 2 clinical trials have shown that MDMA can reduce fear and defensiveness, enhance communication and introspection, and increase empathy and compassion. These combined neurological effects can enhance the therapeutic process for people suffering from PTSD.

About PTSD

PTSD is a serious, long-lasting, and life-threatening condition when not adequately treated, highlighting the need for expedited approval of new therapies. PTSD sufferers may relive their traumatic experiences through nightmares and flashbacks, have difficulty sleeping, and feel detached from daily life. Approximately 7% of the U.S. population, and 11-17% of U.S. military veterans, will have PTSD sometime in their life. As of June 2016, more than 868,000 veterans were receiving disability compensation for PTSD, with an estimated taxpayer cost of $17 billion per year. PTSD is a stress-related condition associated with reduced cognitive and psychosocial functioning, fractured relationships, inability to maintain employment, substance abuse, and increased risk of depression and suicide. In the general population, 27% of suicides are associated with PTSD.

MANTIS_RECOMMEND = { property: '53d026bdee55332b7d413198', render: 'mantis__recommended__wordpress' };

var z = document.createElement("script"); z.type = "text/javascript"; z.async = true; z.src = "//assets.mantisadnetwork.com/recommend.min.js"; var s = document.getElementsByTagName('head')[0]; s.parentNode.insertBefore(z, s);

The post FDA Grants Breakthrough Therapy Designation to MDMA (Ecstasy) for PTSD appeared first on TheJointBlog.

Congressman O’Rourke Introduces Amendment To End Arbitrary License Suspensions

NORML Blog - Mon, 08/28/2017 - 20:39

Congressman Beto O’Rourke (D-TX) with Representatives Amash (R-MI), Jeffries (D-NY), Nadler (D-NY) have introduced an amendment to the appropriations bill that the House is expected to take up next month. The amendment would eliminate the funding for enforcement of Section 159 of title 23, which reduces highway funding for states if they did not automatically suspend drivers licenses of anyone convicted of a drug offense.

This amendment is similar to the Better Drive Act, which Congressman O’Rourke introduced in April. The Better Drive Act removes the federal mandate that demands states to suspend the driver’s license of individuals with a marijuana possession conviction. Currently, any drug conviction, regardless of whether or not the motor vehicle was involved, results in an automatic suspension of the individual’s driving privileges for a period of six months.

Enacted over 25 years ago as a part of the so-called “War on Drugs,” this mandate imposed on states does not improve highway safety or help people address substance abuse. Rather, it had the opposite effect, as this mandate ends up costing minor offenders their ability to get to work and to school, and other undue economic hardships.

By adding an amendment to eliminate the financial penalty against states who do not follow the federal mandate, O’Rourke and his co-sponsors are pushing to ease the burdens against those whom are convicted for simple marijuana possession.

Click here to send a message to you member of the House to support the amendment and companion legislation, The Better Drive Act.

Texas resident? Congressman Beto O’Rourke has been working closely with Texas NORML to address federal reform. Click here to find out more about Texas NORML and follow them on Facebook and Twitter.

Conference of State Legislatures asks to de-schedule cannabis

The Leaf Online - Mon, 08/28/2017 - 19:58

State lawmakers from around the nation called for a new federal law to de-schedule cannabis, allow financial institutions to provide banking services to state-legal marijuana businesses and give states control of their cannabis policies without federal interference. A recent federal review also suggested leaving cannabis policy up to the states. National reform resolution passed The […]

The post Conference of State Legislatures asks to de-schedule cannabis appeared first on The Leaf Online.

Netflix Develops Line of Marijuana Strains Inspired by their Shows

The Joint Blog - Mon, 08/28/2017 - 18:30
In an interesting move, popular streaming service Netflix has developed a line of marijuana strains meant to be consumed with some of their most popular shows.

According to a press release each of the new strains were “cultivated with the specific shows in mind, designed to complement each title based on their tone.” For example, “sillier shows may be more indica dominant, while dramedies will be more sativa dominant to help the more powerful scenes resonate.”

Three of the strains – Omega Strain, Eve’s Bush, and Rutherford B. Haze – were created to compliment one of Netflix’s newest shows Disjointed, about a California-based dispensary owner. Other strains include:

  • The Camp Firefood strain inspired by Wet Hot American Summer: Ten Years Later, described as a “very chill indica”
  • Banana Stand Kush inspired by Arrested Development
  • Vodkush inspired by Chelsea
  • Prickly Muffin inspired by Bojack Horseman
  • Peyotea 73 inspired by Grace and Frankie
  • Sassafrass OG inspired by Lady Dynamite
  • Poussey Riot inspired by Orange in the new Black
  • Baka Bile inspired by Santa Clarita Diet; and
  • Moon 13 inspired by Mystery Science Theater 300 Returns

 

According to Netflix, they aren’t making a profit from these strains, which were developed for promotional purposes.

MANTIS_RECOMMEND = { property: '53d026bdee55332b7d413198', render: 'mantis__recommended__wordpress' };

var z = document.createElement("script"); z.type = "text/javascript"; z.async = true; z.src = "//assets.mantisadnetwork.com/recommend.min.js"; var s = document.getElementsByTagName('head')[0]; s.parentNode.insertBefore(z, s);

The post Netflix Develops Line of Marijuana Strains Inspired by their Shows appeared first on TheJointBlog.

Review: Netflix rolls out 'Disjointed,' starring Kathy Bates, created by TV guru Chuck Lorre

Cannabist - Mon, 08/28/2017 - 17:21
It might take a medicinal brownie or two to really enjoy the new Netflix comedy “Disjointed.”

U.S. Government To Start Releasing Cannabis Industry Employment Data Next Month

Weed News - Mon, 08/28/2017 - 14:45
One of the biggest selling points of marijuana legalization is that it creates a taxed and regulated industry that generates jobs. In my home state (Oregon) the cannabis industry has already...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Beyond Resistance: Ending The Failed War On Drugs

Weed News - Mon, 08/28/2017 - 14:15
It is the 28th day of my email series, “Beyond Resistance: The things we should do to make us safer, healthier, and more economically secure.” Today’s topic: ending the failed War on Drugs. It’s past...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Michigan’s Licensing And Regulatory Affairs To Go On The Road

Weed News - Mon, 08/28/2017 - 13:40
During the Licensing Board meeting on October 21, the Director of the Bureau of Medical Marihuana Regulation (BMMR) revealed a LARA plan to travel across the state to demonstrate the new seed-to-sale...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

CN NS: Tasty Budds President Apologizes After Police Raids And Drug

MAP - Cannabis - Mon, 08/28/2017 - 07:00
Chronicle Herald, 28 Aug 2017 - Tasty Budds president Mal McMeekin is "very sorry" about alleged illegal activities that police say were occuring at his company's storefronts. "We want to be very clear that the alleged illegal activity was occuring at one Tasty Budds location (Sackville Location)," reads a written statement sent to The Chronicle Herald and attributed to Mal McMeekin.

American Legion Resolves In Support Of Expanding Veterans’ Access to Medicinal Cannabis

NORML Blog - Fri, 08/25/2017 - 16:02

The American Legion, the nation’s largest wartime veterans service organization, has adopted a resolution calling on federal officials to expand veterans’ access to medical marijuana.

The resolution, passed yesterday at the Legion’s annual convention, urges the “United States government to permit VA medical providers to be able to discuss with veterans the use of marijuana for medical purposes and recommend it in those states where medical marijuana laws exist.”

The language is similar to pending legislation in Congress, H.R. 1820: The Veterans Equal Access Act. In July, members of the Senate Appropriations Committee voted 24 to 7 to include similar language as an amendment to the 2018 Military Construction, Veterans Affairs and Related Agencies Appropriations bill. Identical language in the House was blocked from consideration by House Rules Chairman Pete Sessions (R-TX).

Last year, majorities in both the US House and Senate voted to include similar language as part of the Fiscal Year 2017 MilCon-VA bill. However, Republicans sitting on the House Appropriations Committee elected to strip the language from the bill during a concurrence vote.

Federal policy prohibits V.A. doctors – including those residing in legal medical cannabis states – from providing the paperwork necessary to complete a recommendation, thus forcing military veterans to seek the advice of a private, out-of-network physician. 

Both the American Legion and AMVETS issued public calls last year for federal marijuana law reforms. Veterans are increasingly turning to medical cannabis as an effective alternative to opioids and other conventional medications to treat conditions like chronic pain and post-traumatic stress

Many Americans use Cannabis for Chronic Pain Because it is Better than Opioids

The Weed Blog - Fri, 08/25/2017 - 16:00

CANNABIS FOR CHRONIC PAIN Currently, 1/3 America suffers from chronic pain, defined as pain that lasts longer than 12 weeks. It commonly coincides alongside secondary symptoms and conditions, from trouble sleeping to a weakened immune system to anxiety and depression. The problem with chronic pain and other health conditions, however, is that many people turn [...]

The post Many Americans use Cannabis for Chronic Pain Because it is Better than Opioids appeared first on The Weed Blog.

Tips for Successfully Growing Marijuana Indoors

The Weed Blog - Fri, 08/25/2017 - 15:12

Tips for Successfully Growing Marijuana Indoors Whether or not you have a green thumb, growing marijuana can be a challenge. If you want to grow your own indoor marijuana plant, you might encounter some trouble. These tips can help you have a successful grow, regardless of the color of your thumb. Do your research Before [...]

The post Tips for Successfully Growing Marijuana Indoors appeared first on The Weed Blog.

American Legion Passes Resolution in Support of Medical Marijuana for Veterans

The Joint Blog - Fri, 08/25/2017 - 07:32
The American Legion, the nation’s largest veterans organization, has passed a resolution calling for a change in federal law to allow medical marijuana for veterans.

The American Legion, which represents over 2.4 million veterans, approved the resolution yesterday at their national convention in Reno, Nevada. Legion member Rob Ryan of Ohio authored the resolution, which calls on the federal government to for allow Department of Veterans Affairs doctors to recommend medical marijuana in states where it’s legal.

“Our state congressmen, when the American Legion says something, they listen”, says Ryan. “Hopefully, this will have the same impact at the federal level. People should not be afraid to go to their doctors and talk honestly.”

Last year the American Legion passed a resolution calls for the government to “amend legislation to remove marijuana from schedule I and reclassify it in a category that, at a minimum will recognize cannabis as a drug with potential medical value.”

MANTIS_RECOMMEND = { property: '53d026bdee55332b7d413198', render: 'mantis__recommended__wordpress' };

var z = document.createElement("script"); z.type = "text/javascript"; z.async = true; z.src = "//assets.mantisadnetwork.com/recommend.min.js"; var s = document.getElementsByTagName('head')[0]; s.parentNode.insertBefore(z, s);

The post American Legion Passes Resolution in Support of Medical Marijuana for Veterans appeared first on TheJointBlog.

CN AB: Local Doc Says Pot Not The Be All, End All

MAP - Cannabis - Fri, 08/25/2017 - 07:00
Medicine Hat News, 25 Aug 2017 - Cannabis will not be the panacea everyone with an ailment is thinking it will be, says a local physician, and it is going to challenge law enforcement when it comes to impaired driving. "If there ever has been an issue in medicine as clouded by opinion and ignorance, it is medical cannabis," said Dr. Gaylord Wardell, anesthesiologist and pain specialist in Medicine Hat.

CN BC: B.C. Medical Marijuana Firm Issues Recall Over Tainted Drugs

MAP - Cannabis - Fri, 08/25/2017 - 07:00
Globe and Mail, 25 Aug 2017 - A Vancouver Island medical marijuana producer has recalled products sold last year after a spot test of its supply by Health Canada showed two pesticides present in a sample of cannabis oil. The recall announced Thursday stems from a crackdown by the federal department in March after months of product recalls dogged the medical-cannabis industry, which is set to make billions of dollars once Ottawa legalizes the drug for recreational use.
Syndicate content